Head and neck cancer fungating wounds: a novel odour transferrer

BMJ Support Palliat Care. 2024 Jan 8;13(e3):e833-e835. doi: 10.1136/spcare-2022-003824.

Abstract

Objective: The management for malodour of malignant fungating wounds (MFWs) in head and neck cancer (HNC) is unestablished. We evaluated the effects of a novel odour transferrer on malodour generated by MFWs in patients with HNC.

Methods: A spray-type odour transferrer approved by the Japanese government for safe use in humans produces a good scent by binding to bad odour. The odour of MFWs in 13 patients with HNC was scored by 37 medical staff and the patients' families using an odour scale ranging from 0 to 4 before and 1 week after application of the odour transferrer.

Results: The odour score marked by all investigators (n=37), nurses (n=21) and doctors (n=11) decreased significantly (p<0.01). The odour score decreased by more than 2 points for 73% of all investigators after odour transferrer application.

Conclusion: This novel odour transferrer functions as an effective deodorant for MFWs in patients with HNC. It can be used by non-medical staff and may benefit patients with bad odours arising from MFWs as well as their families and medical staff.

Keywords: head and neck; hospice care; quality of life; supportive care; terminal care.

MeSH terms

  • Head and Neck Neoplasms*
  • Humans
  • Odorants*